A new HIV prevention medicine could work even better than daily pills, but if nothing changes it costs more than R300,000 to treat one person for a year.
As science-driven research-based pharmaceuticals, IPASA members have played a leading role in the development of effective treatments and vaccines against Covid-19
SHARE
The Covid-19 pandemic provided the pharmaceutical industry with an opportunity to showcase its social value proposition to the world. Not only has society been able to view the direct link between investments in research and development and the production of life-saving drugs, but the world has also witnessed unprecedented global collaboration between the public and private sector to bring these vaccines to market in record time.
With the rise of environmental, social and governance investing and increased demand for companies to align their business practices to the United Nations’ Sustainable Development Goals, the pharmaceutical sector sits in a promising position to improve access to medicine in low- and middle-income countries.